Targeted gene transfer in heart failure: Implications for novel gene identification

Current Opinion in Molecular Therapeutics

Volumn 6, Issue 4, 2004, Pages 381-394

  del Monte, Federica ^a   Kizana, Eddy ^b   Tabchy, Adel ^c   Hajjar, Roger J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b WESTMEAD HOSPITAL   (Australia)

^c Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

adrenergic receptor; Adeno associated virus vector; Gene transfer; Heart failure; Vector delivery

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ADENOVIRUS VECTOR; ALPHA INTERFERON; ANGIOGENIC FACTOR; ANTISENSE OLIGONUCLEOTIDE; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR KINASE INHIBITOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA INTEGRIN; CANCER GROWTH FACTOR; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 14; INTERLEUKIN 4; IONOTROPIC RECEPTOR AGONIST; LENTIVIRUS VECTOR; LIPOSOME; MANGANESE SUPEROXIDE DISMUTASE; MYOSIN HEAVY CHAIN; OLIGONUCLEOTIDE; PLASMID DNA; PLASMID VECTOR; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P35; PROTEINASE; RETROVIRUS VECTOR; SARCOPLASMIC RETICULUM ADENOSINE TRIPHOSPHATASE (CALCIUM); TRANSCRIPTION FACTOR; TROPONIN I; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADENO ASSOCIATED VIRUS; ANGINA PECTORIS; ANGIOGENESIS; BALLOON CATHETER; CELL BASED GENE THERAPY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; GENE CASSETTE; GENE EXPRESSION; GENE IDENTIFICATION; GENE TARGETING; GENE TRANSFER; GENETIC MANIPULATION; GENETIC TRANSCRIPTION; HEART CATHETER; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HUMAN; MITOSIS RATE; MYOCARDIAL DISEASE; MYOCARDITIS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PHENOTYPE; REPERFUSION INJURY; REVIEW; SURGICAL TECHNIQUE; TARGET CELL; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS DNA CELL DNA INTERACTION;

ANIMALS; CALCIUM; CARDIAC OUTPUT, LOW; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, VIRAL; GENETIC VECTORS; HEART; HUMANS; RECEPTORS, ADRENERGIC, BETA; SIGNAL TRANSDUCTION; TRANSGENES;

ADENO-ASSOCIATED VIRUS;

EID: 4444322938     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Hajjar RJ, del Monte F, Matsui T, Rosenzweig A: Prospects for gene therapy for heart failure. Circ Res (2000) 86(6):616-621.
2. Thomas CE, Ehrhardt A, Kay MA: Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet (2003) 4(5):346-358.
3. Nishikawa M, Huang L: Nonviral vectors in the new millennium: Delivery barriers in gene transfer. Hum Gene Ther (2001) 12(8):861-870.
4. Kay MA, Glorioso JC, Naldini L: Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics. Nat Med (2001) 7(1):33-40.
5. Felgner PL: Nonviral strategies for gene therapy. Sci Am (1997) 276(6):102-106.
6. Isner JM: Myocardial gene therapy. Nature (2002) 415(6868):234-239.
7. Nabel EG, Plautz G, Nabel GJ: Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science (1990) 249(4974):1285-1288.
8. Santiago FS, Khachigian LM: Nucleic acid based strategies as potential therapeutic tools: Mechanistic considerations and implications to restenosis. J Mol Med (2001) 79(12):695-706.
9. Liu F, Qi H, Huang L, Liu D: Factors controlling the efficiency of cationic lipid-mediated transfection in vivo via intravenous administration. Gene Ther (1997) 4(6):517-523.
10. Qin XQ, Tao N, Dergay A, Moy P, Fawell S, Davis A, Wilson JM, Barsoum J: Interferon-β gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc Natl Acad Sci USA (1998) 95(24):14411-14416.
11. Wahlfors J, Morgan RA: Semliki Forest virus vectors for gene transfer. Methods Mol Med (2003) 76:493-502.
12. Guzman RJ, Hirschowitz EA, Brody SL, Crystal RG, Epstein SE, Finkel T: In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci USA (1994) 91(22):10732-10736.
13. Barr E, Carroll J, Kalynych AM, Tripathy SK, Kozarsky K, Wilson JM, Leiden JM: Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus. Gene Ther (1994) 1(1):51-58.
14. Communal C, Huq F, Lebeche D, Mestel C, Gwathmey JK, Hajjar RJ: Decreased efficiency of adenovirus-mediated gene transfer in aging cardiomyocytes. Circulation (2003) 107(8):1170-1175.
15. Hajjar RJ, Schmidt U, Matsui T, Guerrero JL, Lee KH, Gwathmey JK, Dec GW, Semigran MJ, Rosenzweig A: Modulation of ventricular function through gene transfer in vivo. Proc Natl Acad Sci USA (1998) 95(9):5251-5256.
16. Shohet RV, Chen S, Zhou YT, Wang Z, Meidell RS, Unger RH, Grayburn PA: Echocardiographic destruction of albumin microbubbles directs gene delivery to the myocardium. Circulation (2000) 101(22):2554-2556.
17. Beeri R, Guerrero JL, Supple G, Sullivan S, Levine RA, Hajjar RJ: New efficient catheter-based system for myocardial gene delivery. Circulation (2002) 106(14):1756-1759.
18. Donahue JK, Kikkawa K, Johns DC, Marban E, Lawrence JH: Ultrarapid, highly efficient viral gene transfer to the heart. Proc Natl Acad Sci USA (1997) 94(9):4664-4668.
19. Donahue JK, Kikkawa K, Thomas AD, Marban E, Lawrence JH: Acceleration of widespread adenoviral gene transfer to intact rabbit hearts by coronary perfusion with low calcium and serotonin. Gene Ther (1998) 5(5):630-634.
20. Nagata K, Marban E, Lawrence JH, Donahue JK: Phosphodiesterase inhibitor-mediated potentiation of adenovirus delivery to myocardium. J Mol Cell Cardiol (2001) 33(3):575-580.
21. Lemarchand P, Jones M, Yamada I, Crystal RG: In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors. Circ Res (1993) 72(5):1132-1138.
22. Gratton JP, Yu J, Griffith JW, Babbitt RW, Scotland RS, Hickey R, Giordano FJ, Sessa WC: Cell-permeable peptides improve cellular uptake and therapeutic gene delivery of replication-deficient viruses in cells and in vivo. Nat Med (2003) 9(3):357-362.
23. Monahan PE, Samulski RJ: Adeno-associated virus vectors for gene therapy: More pros than cons? Mol Med Today (2000) 6(11):433-440.
24. Monahan PE, Samulski RJ, Tazelaar J, Xiao X, Nichols TC, Bellinger DA, Read MS, Walsh CE: Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther (1998) 5(1):40-49.
25. Monahan PE, Samulski RJ: AAV vectors: Is clinical success on the horizon? Gene Ther (2000) 7(1):24-30.
26. Xiao X, Li J, Samulski RJ: Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol (1998) 72(3):2224-2232.
27. A α1 containing receptors and increases inferior collicular seizure sensitivity. Brain Res (1997) 756(1-2):76-83.
28. Xiao X, Li J, McCown TJ, Samulski RJ: Gene transfer by adeno-associated virus vectors into the central nervous system. Exp Neurol (1997) 144(1):113-124.
29. Xiao X, Xiao W, Li J, Samulski RJ: A novel 165-base-pair terminal repeat sequence is the sole cis requirement for the adeno-associated virus life cycle. J Virol (1997) 71(2):941-948.
30. Hildinger M, Auricchio A, Gao G, Wang L, Chirmule N, Wilson JM: Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer. J Virol (2001) 75(13):6199-6203.
31. Chao H, Mao L, Bruce AT, Walsh CE: Sustained expression of human factor VIII in mice using a parvovirus-based vector. Blood (2000) 95(5):1594-1599.
32. Rutledge EA, Halbert CL, Russell DW: Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J Virol (1998) 72(1):309-319.
33. Li J, Wang D, Qian S, Chen Z, Zhu T, Xiao X: Efficient and long-term intracardiac gene transfer in δ-sarcoglycan-deficiency hamster by adeno-associated virus-2 vectors. Gene Ther (2003) 10(21 ):1807-1813.
34. Hoshijima M, Ikeda Y, Iwanaga Y, Minamisawa S, Date MO, Gu Y, Iwatate M, Li M, Wang L, Wilson JM, Wang Y et al. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med (2002) 8(8):864-871.
35. Richter M, Iwata A, Nyhuis J, Nitta Y, Miller AD, Halbert CL, Allen MD: Adeno-associated virus vector transduction of vascular smooth muscle cells in vivo. Physiol Genomics (2000) 2(3):117-127.
36. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, Morecki S, Andolfi G, Tabucchi A, Carlucci F, Marinello E et al: Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science (2002) 296(5577):2410-2413.
37. Gaspar H, Howe S, Thrasher A: Gene therapy progress and prospects: Gene therapy for severe combined immunodeficiency. Gene Ther (2003) 10(24):1999-2004.
38. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bousso P et al: Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science (2000) 288(5466):669-672.
39. Nabel EG, Barry J, Rocco MB, Mead K, Selwyn AP: Effects of dosing intervals on the development of tolerance to high dose transdermal nitroglycerin. Am J Cardiol (1989) 63(11):663-669.
40. Nabel EG, Plautz G, Boyce FM, Stanley JC, Nabel GJ: Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science (1989) 244(4910):1342-1344.
41. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, Fischer A: A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med (2003) 348(3):255-256.
42. Hacein-Bey-Abina S, de Saint Basile G, Cavazzana-Calvo M: Gene therapy of X-linked severe combined immunodeficiency. Methods Mol Biol (2003) 215:247-259.
43. Klages N, Zufferey R, Trono D: A stable system for the high-titer production of multiply attenuated lentiviral vectors. Mol Ther (2000) 2(2):170-176.
44. Trono D: Lentiviral vectors: Turning a deadly foe into a therapeutic agent. Gene Ther (2000) 7(1):20-23.
45. Galimi F, Verma IM: Opportunities for the use of lentiviral vectors in human gene therapy. Curr Top Microbiol Immunol (2002) 261:245-254.
46. Zennou V, Petit C, Guetard D, Nerhbass U, Montagnier L, Charneau P: HIV-1 genome nuclear import is mediated by a central DNA flap. Cell (2000) 101(2):173-185.
47. Bonci D, Cittadini A, Latronico MV, Borello U, Aycock JK, Drusco A, Innocenzi A, Follenzi A, Lavitrano M, Monti MG, Ross J Jr et al: 'Advanced' generation lentiviruses as efficient vectors for cardiomyocyte gene transduction in vitro and in vivo. Gene Ther (2003) 10(8):630-636.
48. Kaneda Y, Saeki Y, Morishita R: Gene therapy using HVJ-liposomes: The best of both worlds? Mol Med Today (1999) 5(7):298-303.
49. Kaneda Y: Development of a novel fusogenic viral liposome system (HVJ-liposomes) and its applications to the treatment of acquired diseases. Mol Memb Biol (1999) 16(1):119-122.
50. Boecker W, Bernecker OY, Wu JC, Zhu X, Sawa T, Grazette L, Rosenzweig A, del Monte F, Schmidt U, Hajjar RJ: Cardiac specific gene expression facilitated by an enhanced myosin light chain promoter. Mol Imaging (2004) 3(2):69-75.
51. Agha-Mohammadi S, Lotze MT: Regulatable systems: Applications in gene therapy and replicating viruses. J Clin Invest (2000) 105(9):1177-1183.
52. Agha-Mohammadi S, Lotze MT: Immunomodulation of cancer: Potential use of selectively replicating agents. J Clin Invest (2000) 105(9):1173-1176.
53. Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Ledley FD, Lotze MT, Wilson JM, Nabel GJ, Cornetta K, Economou JS, Freeman SM et al: Human gene marker/therapy clinical protocols. Hum Gene Ther (2000) 11(6):919-979.
54. Feldman LJ, Pastore CJ, Aubailly N, Kearney M, Chen D, Perricaudet M, Steg PG, Isner JM: Improved efficiency of arterial gene transfer by use of poloxamer 407 as a vehicle for adenoviral vectors. Gene Ther (1997) 4(3):189-198.
55. Feldman LJ, Steg G: Optimal techniques for arterial gene transfer. Cardiovasc Res (1997) 35(3):391-404.
56. Marshall E: Improving gene therapy's tool kit. Science (2000) 288(5468):953.
57. Marshall J, Nietupski JB, Lee ER, Siegel CS, Rafter PW, Rudginsky SA, Chang CD, Eastman SJ, Harris DJ, Scheule RK, Cheng SH: Cationic lipid structure and formulation considerations for optimal gene transfection of the lung. J Drug Targeting (2000) 7(6):453-469.
58. Tsui LV, Zayek N, Frey D, Mello C, Banik G, Falotico R, McArthur JG: Stability of adenoviral vectors following catheter delivery. Mol Ther (2001) 3(1):122-125.
59. Tsui LV, Camrud A, Mondesire J, Carlson P, Zayek N, Camrud L, Donahue B, Bauer S, Lin A, Frey D, Rivkin M et al: p27-p16 fusion gene inhibits angioplasty-induced neointimal hyperplasia and coronary artery occlusion. Circ Res (2001) 89(4):323-328.
60. Donahue JK, Heldman AW, Fraser H, McDonald AD, Miller JM, Rade JJ, Eschenhagen T, Marban E: Focal modification of electrical conduction in the heart by viral gene transfer. Nat Med (2000) 6(12):1395-1398.
61. Koransky ML, Robbins RC, Blau HM: VEGF gene delivery for treatment of ischemic cardiovascular disease. Trends Cardiovasc Med (2002) 12(3):108-114.
62. Edelberg JM, Huang DT, Josephson ME, Rosenberg RD: Molecular enhancement of porcine cardiac chronotropy. Heart (2001) 86(5):559-562.
63. Losordo DW, Kawamoto A: Biological revascularization and the interventional molecular cardiologist: Bypass for the next generation. Circulation (2002) 106(24):3002-3005.
64. Isner JM, Vale PR, Symes JF, Losordo DW: Assessment of risks associated with cardiovascular gene therapy in human subjects. Circ Res (2001) 89(5):389-400.
65. Boekstegers P, von Degenfeld G, Giehrl W, Heinrich D, Hullin R, Kupatt C, Steinbeck G, Baretton G, Middeler G, Katus H, Franz WM: Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins. Gene Ther (2000) 7(3):232-240.
66. Kupatt C, Wichels R, Deiss M, Molnar A, Lebherz C, Raake P, von Degenfeld G, Hahnel D, Boekstegers P: Retroinfusion of NFκB decoy oligonucleotide extends cardioprotection achieved by CD18 inhibition in a preclinical study of myocardial ischemia and retroinfusion in pigs. Gene Ther (2002) 9(8):518-526.
67. Guzman RJ, Lemarchand P, Crystal RG, Epstein SE, Finkel T: Efficient gene transfer into myocardium by direct injection of adenovirus vectors. Circ Res (1993) 73(6):1202-1207.
68. Fromes Y, Salmon A, Wang X, Collin H, Rouche A, Hagege A, Schwartz K, Fiszman MY: Gene delivery to the myocardium by intrapericardial injection. Gene Ther (1999) 6(4):683-688.
69. Christensen G, Minamisawa S, Gruber PJ, Wang Y, Chien KR: High-efficiency, long-term cardiac expression of foreign genes in living mouse embryos and neonates. Circulation (2000) 101(2):178-184.
70. Hajjar RJ, del Monte F, Matsui T, Rosenzweig A: Prospects for gene therapy for heart failure. Circ Res (2000) 86(6):616-621.
71. Hajjar RJ: The promise of gene therapy as a therapeutic modality in heart failure. J Med Libanais (2000) 48(2):86-88.
72. 2+-ATPase in a rat model of heart failure. Circulation (2001) 104(12):1424-1429.
73. Lohse MJ, Engelhardt S, Eschenhagen T: What is the role of β-adrenergic signaling in heart failure? Circ Res (2003) 93(10 ):896-906.
74. Lohse MJ, Engelhardt S: Protein kinase A transgenes: The many faces of cAMP. Circ Res (2001) 89(11):938-940.
75. Bristow M, Port JD: β-Adrenergic blockade in chronic heart failure. Scand Cardiovasc J Suppl (1998) 47:45-55.
76. Bristow MR: Why does the myocardium fail? Insights from basic science. Lancet (1998) 352(Suppl 1):Sl8-S14.
77. Engelhardt S, Hein L, Wiesmann F, Lohse MJ: Progressive hypertrophy and heart failure in β1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 1999 96(12):7059-7064.
78. Shah AS, White DC, Emani S, Kypson AP, Lilly RE, Wilson K, Glower DD, Lefkowitz RJ, Koch WJ: In vivo ventricular gene delivery of a β-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. Circulation (2001) 103(9):1311-1316.
79. Port JD, Bristow MR: Altered β-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol (2001) 33(5):887-905.
80. Balke CW, Gold MR: Excitation-contraction-relaxation coupling in the normal and failing heart. Heart Dis Stroke (1993) 2(2):150-155.
81. Bristow MR, Shakar SF, Linseman JV, Lowes BD: Inotropes and β-blockers: Is there a need for new guidelines? J Cardiac Failure (2001) 7(2 Suppl 1):8-12.
82. del Monte F, Harding SE, Schmidt U, Matsui T, Kang ZB, Dec GW, Gwathmey JK, Rosenzweig A, Hajjar RJ: Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation (1999) 100(23):2308-2311.
83. del Monte F, Harding SE, Dec GW, Gwathmey JK, Hajjar RJ: Targeting phospholamban by gene transfer in human heart failure. Circulation (2002) 105(8):904-907.
84. Terracciano CM, Hajjar RJ, Harding SE: Overexpression of SERCA2a accelerates repolarisation in rabbit ventricular myocytes. Cell Calcium (2002) 31(6):299-305.
85. Morishita R, Aoki M, Nakamura S, Matsushita H, Tomita N, Hayashi S, Moriguchi A, Matsumoto K, Nakamura T, Higaki J, Ogihara T: Potential role of a novel vascular modulator, hepatocyte growth factor (HGF), in cardiovascular disease: Characterization and regulation of local HGF system. J Atheroscler Thromb (1997) 4(1):12-19.
86. Hirota H, Chen J, Betz UA, Rajewsky K, Gu Y, Ross J Jr, Muller W, Chien KR: Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell (1999) 97(2):189-198.
87. Hirota J, Furuichi T, Mikoshiba K: Inositol 1,4,5-trisphosphate receptor type 1 is a substrate for caspase-3 and is cleaved during apoptosis in a caspase-3-dependent manner. J Biol Chem (1999) 274(48):34433-34437.